OLIO
OLIO
Red Cross
Unicef
Unicef
Aalto Ventures
Beta-i
Imperus
IBM
Zapper
CamFind
Splash VR
Prelude Fertility
UNICEF Ventures
Co-Founder, UNICEF Innovation Lab
Christopher Fabian (@hichrisfabian on Twitter) (born April 18, 1980) is a technologist and innovator who co-leads UNICEF'sInnovation Un alongside Erica Kochi. Fabian works on finding solutions to big problems that face humanity, particularly children. Since 2007 he has held the title of Senior Advisor on Innovation to the Executive Director at UNICEF and Co-founder and Co-lead of the UNICEF Innovation Unit. He is best known for his work on tools for children and communities in low-infrastructure environments. Solutions he has worked on include the Digital Drum, U-Report, and RapidSMS, which has evolved to RapidPro—the free, open source framework for rapidly building mobile services for scale. In 2015 he led on the launch of UNICEF’s Innovation Fund, a pooled funding vehicle built to quickly assess, fund and scale companies, teams, and ideas that have been developed in new and emerging markets. In 2013, he and Kochi were selected by Time magazine to be on the Time 100 list of the 100 most influential people in the world.
Head of Connected Cars at Mercedes-Benz
Christoph Hartung is the Head of Connected Car, Mercedes-Benz Cars at Daimler AG since March 2015.
Christoph's prior roles at Daimler AG includes, from 2013 to 2015, Head of Customer Management Mercedes-Benz Cars & Mercedes-Benz 2020, from 2010 to 2013, Head of IT Global Service & Parts Member of the Board of Management Global Service & Parts, from 2006 to 2010, Senior Manager of Workshop Systems and Retail Integration, from 2002 to 2006, Senior Manager Global Platforms and Architectures, from 2000 to 2002, Executive Assistant to the Vice President of IT Business Systems and from 1999 to 2000, International Management Associate Program (AMCT).
Christoph earned his M.S. in Computer and Information Science from University of Massachusetts, Dartmouth and his Diploma in Industrial Engineering and Business Planning from Karlsruhe Institute of Technology.
Founder & CEO at Blonde 2.0
Ayelet Noff is the founder of award-winning PR Firm Blonde 2.0. Founded in 2006, Blonde 2.0 is situated right at the heart of the startup nation and specializes in marketing and publicizing technology companies. The firm has 25 employees from all around the world and helps 60 companies such as Hewlett-Packard, Applied Materials, Viber, StoreDot, Applause, Yo, and more, to receive coverage in major publications, engage with consumers and influencers, and create a consistent buzz on the Web and beyond.
Executive Director Global Crop Diversity Trust
Marie Haga joined the Global Crop Diversity Trust as Executive Director in March 2013. She had previously been member and Deputy Chair of the Global Crop Diversity Trust Executive Board.
Ms. Haga has a background from Foreign Service as a career diplomat, from politics and private sector.
She has held various positions in the Norwegian Ministry of Foreign Affaires including to the Norwegian Mission to the United Nations in New York and the Embassy in New Delhi. She was politically appointed and held the position as State Secretary/Deputy Minister in the Ministry of Foreign Affaires 1997-1999.
Ms. Haga has wide experience from politics and served as a Member of Parliament in Norway from 2001-2009. She was political advisor to the Minister for Development Cooperation from 1997-1998. She was Chairperson of the Centre Party from 2003- 2008. Ms. Haga has held three Ministerial positions: Minister of Cultural Affairs (1999- 2000), Minister of Local Government and Regional Development (2005-2007) and Minister of Petroleum and Energy (2007-2008).
Marie Haga has held the position as Director for Renewable Energy in the Federation of Norwegian Industries (2009-2011) and as Secretary General of the Norwegian Air Ambulance (2011-2013) - the biggest voluntary organization in Norway.
Ms. Haga has been on several boards, including as Chair of the Governing Board of the Norwegian Institute for Nature Research (NINA) (2009-2013) and Chair of the Governing Board of the Industrial Development Corporation of Norway (2010-2013). She currently serves on the Board of Directors of the Regional Environmental Center (REC).
Marie Haga has also published three books - one novel and two on Norwegian politics.
Project Director, Barcelona Biomedical Research Park (PRBB)
In recent years life sciences have become “Big Science”. Just one indicator. The web of the main database for biological information at the European Molecular Biology Laboratory (EMBL) receives 16 million tasks per day, 8 times more than the data centre of the nuclear research centre CERN in Geneva. Every day scientists in life sciences and biomedicine get more insights about biological systems and are learning to translate them into applications to improve our health and fight diseases. An overview will be given on latest research results from molecules to populations. Also the upcoming topics on brain research, synthetic biology and advances in drug development will be introduced.
Group leader at the Hospital del Mar Medical Research Institute (IMIM), Barcelona
The brain is by far the most complex organ in your body. Neuroscientists have figured out many things about the organization and specialization of the different areas of the brain but there´s still a long way to go to cure brain disorders. In this presentation I will talk about the cellular substrates of your thoughts and feelings, and what makes you how you are. I will explain how populations of neurons organize in complex neural networks that communicate to each other via brain waves and how we can erase nasty memories. I will also describe new ways of changing brain activity to cure brain disorders or enhance innate abilities. These include closed-loop deep brain stimulation and optogenetics, two new techniques that are revolutionizing brain science.
Staff scientist at the Centre for Genomic Regulation (CRG), Barcelona
Nowadays, therapies are based on chemical compounds or proteins. However, with the advent of genomics, we realize that different genetic background could make that each person responds differently the same compound. Not only the different genetic background but also the microbiome, variety of microorganisms living in association with the human body, can determine this diversity in the treatment responses. Moreover, chemical compounds and proteins cannot sense and respond to the individual circumstances. Thus, engineering bacteria that are part of this microbiomes to supply proteins with therapeutical applications is one of the main challenges in Synthetic Biology. In our lab, we have developed a bottom-top approach to characterize deeply a minimal bacterium, Mycoplasma pneumoniae. Despite this bacterium is a human lung pathogen, it only causes atypical pneumonia in inmunodepressed patients and infections can be easily treated by using antibiotics. Also, its small genome converts this microorganisms as unique model for a quantitative understanding of a living system. During almost one decade in our lab we have characterized M. pneumoniae by different “omics” and it has allowed us to design the first computational whole-cell model that could predict the impact of genome engineering in silico. Within different European projects, my colleagues and I will design a universal and living chassis that could be used for different applications: living vaccine (MycoSynVac) and as delivery system (MiniCell). I will present the planned workflow including whole-cell modelling, genome-editing, transplantation tools, circuit (re-) design and chassis plug-ins.
Group leader at the Institute of Evolutionary Biology (IBE) and Professor at the Pompeu Fabra University (UPF)
Mounting evidence indicates that our planet might experience runaway effects associated to rising temperatures and ecosystem overexploitation, leading to catastrophic shifts on short time scales. We hypothesize that synthetic organisms with the appropriate engineering design could be used to safely prevent declines in some stressed ecosystems and help improving carbon sequestration. Such schemes would include engineering mutualistic dependencies preventing undesired evolutionary processes. We hypothesize that some particular design principles introduce unescapable constraints to the engineered organisms that act as effective firewalls. To save the planet, we might need to redesign it.
CEO of Mind the Byte, Barcelona, and Copenhagen
Drug development is a long and expensive process (up to 20 years and around $1300 M). Time and costs can be reduced by using computational models, named computational drug discovery. These methods can save up to 3 years and up to 40% costs. Main problem remains on the adoption of this technology (economic, training and technology barriers).
These barriers can be solved by using new business models (the adoption of SaaS-cloud approaches to deliver the software can skip all investments) and also new technologies, such as Big Data and Machine learning. By using technologies not used before on the field we can make computational drug discovery something better, more accessible, and accelerate time to market for new drugs, reducing costs and helping researchers to find better remedies for unsolved diseases.
CEO of ZeClinics, Barcelona
The impact of cancer in our society is enormous, 1 out of 3 people suffer it and it is the second cause of death worldwide. But the most challenging aspect is that each cancer patient is different from any other, no general drugs exist for curing all types of cancer and in the 30% of cases the treatment given to a patient does not work, with a consequent cascade of dramatic events, eventually ending in death.
At ZeClinics we are specialized in using zebrafish, a little tropical fish ‘very similar to humans’, for drug discovery and biomedicine research. With zebrafish we plan to disrupt the classical way of selecting the best anti-tumour treatment for each and every cancer patient. We do that by transplanting parts of the tumour directly from patient to a battery of fishes and treat them with different available medicines. Out of the transplanted fishes we generate a personalized anti-tumour chemical profile helping the oncologist to make the right choice. This is the ZeOncoTest, a new disruptive approach against the clock of cancer.
Chief Executive Officer at Euronews and Africanews
Born in 1971 in Flensburg, Germany, of French and German nationality, Michael Peters graduated from EM Lyon business school with a Master’s degree in Financial Engineering (1995) and from IAE Lyon III (1992).
He began his career at the international auditing firm of Arthur Andersen, in Lyon, France (1995-1998).
Michael Peters joined Euronews in 1998 as Finance Manager and then became CFO. He was appointed Deputy Managing Director of Euronews in December 2003.
In May 2005, at the age of 33, and seven years after joining Euronews, Michael Peters was appointed Managing Director of Europe’s leading news channel. In December 2008, Michael Peters was appointed Managing Director of the Executive Board of Euronews S.A.
In December 2011, Michael Peters was appointed Chairman of the Executive Board of Euronews, based in Lyon, France.
In August 2014, Michael Peters was appointed President of Africanews, based in Pointe-Noire, Republic of Congo. The news media for Africa was launched in 2016.
Co-founder of Bitty Foods
Born in 1971 in Flensburg, Germany, of French and German nationality, Michael Peters graduated from EM Lyon business school with a Master’s degree in Financial Engineering (1995) and from IAE Lyon III (1992).
Leslie Ziegler is the cofounder of Bitty Foods, a company introducing edible insects to the western diet in the form of cricket flour—an incredible superfood high in protein, fiber and other nutrients. Founded in 2014, Bitty was named one of Entrepreneur Magazine's 100 Brilliant Companies and has received international accolades in the New York Times, Elle, Vogue, Vice, Outside, Men's Health and Food & Wine. Our new Chiridos chips were just named one of the Top 5 Food Trends at the Fancy Food Show, and were a finalist for best new snack at ExpoWest.
Leslie also serves as an advisor and board member to several startups at the convergence of health and technology including Foodoo, Maven, Neurotrack and Other. Previously, she was part of the founding team at Rock Health, an incubator focused on digital health, serving primarily as the firm’s creative director and chief evangelist. Leslie speaks internationally on health, design and technology, most recently at SXSW, Chicago Ideas Week, WIRED and CES, and has been featured in publications including Fast Company, NPR, Time, GQ, Entrepreneur, Inc, Vogue, and The New York Times.Angel Investor and Advisor
Born in 1971 in Flensburg, Germany, of French and German nationality, Michael Peters graduated from EM Lyon business school with a Master’s degree in Financial Engineering (1995) and from IAE Lyon III (1992).
LSofia is an entrepreneurial investor on a mission to find and develop the visionary high-impact & world-class entrepreneurs using technology to solve intractable challenges, disrupt markets and create global impact.
These are businesses have advantages in the market that can outperform their more traditional peers: they are purpose-driven and benefit-focused by nature, they create revolutionary products and technologies to address global needs or improve our lives, and they generate remarkable profits that fuel market-leading growth and expanding reach. Sofia has been recognised by the World Economic Forum as a Global Shaper, by Founders Forum as a Founder of the Future, and by the French government as an expert advisor to the “France 2020” project. Sofia’s remarkable career at the intersection of tech innovation and investment encompasses successful stints at Index Ventures, Europe’s top venture capital firm, and with angel investor Robin Klein. Prior to this, at the worldwide digital music service Deezer, she was tasked with raising investment round funds of $130 million before becoming the business’s Global Strategy Manager, coordinating international expansion and opening 15 worldwide offices. In 2016, Sofia launched her own initiative: a collaborative investment network designed to foster visionary enterprises that use the propulsive power of business to create positive global progress – the culmination of a career combining principled action and a belief in disruptive ideas with incisive business aptitude. Purpose-driven and rigorously execution-focused, Sofia’s personal and professional passions were directed for more than a decade towards impactful non-profit ventures, founding and steering four groundbreaking programmes. One such project, literacy initiative Laboratoire des Histoires, was singled out by the French government to receive multi-million-Euro investment and rolled out nationwide. With her international experience, intellectual and philosophical curiosity and a love of rapid-fire conversation (in no less than four languages), Sofia is also an engaging and sought-after speaker and mentor. She’s also the powerhouse behind Impact Coffee, where you’ll regularly find her, mocha in hand, asking big questions and making big ideas happen.Director Vehicle Automation, Daimler AG
Ralf G. Herrtwich creates self-driving vehicles for Mercedes-Benz. In 2013, his team made an S-Class re-enact the world’s first overland drive, covering the historic 65-miles Bertha Benz Route autonomously in regular traffic. As Director of Vehicle Automation and Chassis Systems, Dr. Herrtwich is in charge of conceiving and developing future safety and comfort innovations for Daimler vehicles. A computer scientist by education, he started his career in academia at TU Berlin and UC Berkeley. He then held management positions with IBM and several telecommunication startups before joining Daimler in 1998 to manage its research on telematics and in-car infotainment. Since 2009, he also is honorary professor for vehicle information technology at TU Berlin.
Partner at Medicxi Ventures
Prior to co-founding Medicxi Ventures, Francesco was with Index Ventures for 18 years, having joined the firm in 1997 to launch its life sciences practice. While at Index life sciences, he spearheaded the creation and adoption of the asset-centric investment strategy and led the growth of the firm. At Medicxi he also oversees the firm’s operations.
Francesco has been a member of the board of directors of 25-30 companies and he chairs the life sciences task force of the European Venture Capital Association (EVCA).
Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral scientist at the Whitehead Institute at MIT. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva.
Francesco was named by BioWorld as one of 28 “movers and shakers” predicted to shape the biotechnology industry over the next two decades.
CEO at YNSECT
Mr. Antoine Hubert is Chairman, CEO and co-founder of YNSECT – The Insect Company – and also President & co-founder of the International Platform of Insects for Food & Food (IPIFF).
Antoine Hubert was previously senior scientist at TOTAL and ALTRAN where he managed R&D; programs on Sustainable Development applied on bioresources, soil remediation, waste-to-energy and recycled resources. He also launched in 2007 and led the non-profit organization WORGAMIC, dealing with food sustainability, promoting urban agriculture and organic waste recycling within cities, and in 2011 the company ORGANEO operating on biowaste management.
He is also Guest Lecturer in different Agro Schools and Universities, like AgroParisTech. He has a background in agronomy and life sciences from AgroCampus Rennes and AgroParisTech Engineering schools.
Vice chair, UNICEF Spain; Co-Founder, K Fund
MEx – banker, with more than 22 years of experience working for that industry. A rebel banker, as she challenged the industry being part of the “founders” team at ING Direct in Spain, the leader in online banking. She became CEO of ING Direct France and after that of ING Direct Spain, setting the path for being the most advanced digital bank and the preferred bank of the consumers.
In 2013 started to cooperate with Unicef as Vice chair of the Spanish committee to boost the digital opportunities in cooperation. She also contributes to the innovation of other companies in her role as Independent Director in the Boards of Abanca, Grifols and Melia Hoteles.
Carina’s most recent endeavor is co-founding of K Fund, a new VC in Spain that will contribute to the creation of new companies, more innovative, more customer centric, that really connect technology with people, to demonstrate that Spain can create big, solid, modern and global companies.
She is convinced that “through connecting generosity we can create magic”, that is why the world belongs to the “givers”, not to the takers.
Avda. Barcelona
T. 9335 0863 300 F. 9355 0862 333
View on Google Maps
Check Poble Espanyol's directory to find more information about its shops, craft workshops, delicatessen shops and restaurants here